| ADCC | Antibody-Dependent Cell-Mediated Cytotoxicity |
| AT | Adjuvant Therapy |
| CS | Carcinosarcoma |
| CSCs | Cancer Stem Cells |
| DM1 | Maytansinoid Cytotoxin |
| EMA | Epithelial Membrane Antigen |
| ErbB family | Human Epidermal Growth Factor Family of Receptors |
| FDA | Food and Drug Administration |
| FIGO | International Federation of Gynecology and Obstetrics |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| MMT | Malignant Mixed Müllerian Tumor |
| CD10 | Cluster of Differentiation 10 |
| EpCAM | Epithelial Cell Adhesion Molecule-1 |
| SEM | Standard Error of the Mean |
| T | Trastuzumab |
| T-DM1 | Trastuzumab Emtansine |
| VEGF | Vascular Endothelial Growth Factor |
| μM | Micromole |
| NK | Natural Killer |
| DCs | Dendritic Cells |
| TACE | Tumor Necrosis Factor-Alpha Converting Enzyme |
| EpICD | Epithelial Cell Intra-Cellular Domain |
| FHL2 | Four and a Half LIM Domain 2 |
| HLA-DR | Human Leukocyte Antigens D Related |
| TICs | Tumor Infiltrating Cells |